Tempest Therapeutics (TPST) Gross Margin (2015 - 2018)
Tempest Therapeutics (TPST) posted Gross Margin of 20.0% for Q3 2018, down 40.0% sequentially from 33.33% in Q2 2018, and down 2821.0% YoY from 0.74% in Q3 2017.
Tempest Therapeutics (TPST) Gross Margin (2015 - 2018) Analysis & Trends
Tempest Therapeutics has reported Gross Margin for 4 years, with the latest figure at 20.0% in Q3 2018.
- Quarterly Gross Margin fell 2821.0% year-over-year to 20.0% in Q3 2018, while the trailing twelve-month figure through Sep 2018 was 45.58% (up 47325.0% YoY) and the FY2017 annual result came in at 167.8%, up 55931.0% from the prior year.
- Gross Margin retreated to 20.0% in Q3 2018 per TPST's latest filing, from 33.33% in the prior quarter.
- Over five years, Gross Margin peaked at 48.21% in Q3 2017 and troughed at 1153.33% in Q3 2015.
- A 4-year average of 393.52% and a median of 286.67% in 2015 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2016 and 2017: Gross Margin tumbled 57215 bps in 2016, then surged 94474 bps in 2017.
- Over 4 years, Gross Margin stood at 637.58% in 2015, then slumped by 70 bps to 1084.3% in 2016, then soared by 87 bps to 139.56% in 2017, then surged by 114 bps to 20.0% in 2018.
- According to Business Quant data, Gross Margin over the past three periods registered 20.0%, 33.33%, and 67.16% for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 20.00% |
| Jun 30, 2018 | 33.33% |
| Mar 31, 2018 | -67.16% |
| Dec 31, 2017 | -139.56% |
| Sep 30, 2017 | 48.21% |
| Jun 30, 2017 | -226.19% |
| Mar 31, 2017 | -326.98% |
| Dec 31, 2016 | -1,084.30% |
| Sep 30, 2016 | -691.37% |
| Jun 30, 2016 | -552.38% |
| Mar 31, 2016 | -705.48% |
| Dec 31, 2015 | -637.58% |
| Sep 30, 2015 | -1,153.33% |
| Jun 30, 2015 | -286.67% |
| Mar 31, 2015 | -133.33% |